Akoya Biosciences Inc
NASDAQ:AKYA
Intrinsic Value
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. [ Read More ]
The intrinsic value of one AKYA stock under the Base Case scenario is 15.34 USD. Compared to the current market price of 3.81 USD, Akoya Biosciences Inc is Undervalued by 75%.
Valuation Backtest
Akoya Biosciences Inc
Run backtest to discover the historical profit from buying and selling AKYA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Akoya Biosciences Inc
Current Assets | 121.8m |
Cash & Short-Term Investments | 83.1m |
Receivables | 17m |
Other Current Assets | 21.7m |
Non-Current Assets | 58.6m |
PP&E | 21.5m |
Intangibles | 35.7m |
Other Non-Current Assets | 1.4m |
Current Liabilities | 35.3m |
Accounts Payable | 11.8m |
Accrued Liabilities | 13.1m |
Other Current Liabilities | 10.5m |
Non-Current Liabilities | 91.3m |
Long-Term Debt | 76m |
Other Non-Current Liabilities | 15.2m |
Earnings Waterfall
Akoya Biosciences Inc
Revenue
|
96.6m
USD
|
Cost of Revenue
|
-40.3m
USD
|
Gross Profit
|
56.3m
USD
|
Operating Expenses
|
-114m
USD
|
Operating Income
|
-57.7m
USD
|
Other Expenses
|
-5.7m
USD
|
Net Income
|
-63.3m
USD
|
Free Cash Flow Analysis
Akoya Biosciences Inc
AKYA Profitability Score
Profitability Due Diligence
Akoya Biosciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Akoya Biosciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
AKYA Solvency Score
Solvency Due Diligence
Akoya Biosciences Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Akoya Biosciences Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AKYA Price Targets Summary
Akoya Biosciences Inc
According to Wall Street analysts, the average 1-year price target for AKYA is 9.01 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.
Ownership
AKYA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AKYA Price
Akoya Biosciences Inc
Average Annual Return | -31.48% |
Standard Deviation of Annual Returns | 8.95% |
Max Drawdown | -88% |
Market Capitalization | 187.1m USD |
Shares Outstanding | 49 140 700 |
Percentage of Shares Shorted | 3.14% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 319 full-time employees. The company went IPO on 2021-04-16. The firm deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. The company provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. The company offers contract research services laboratory, which is called as advanced biopharma solutions.
Contact
IPO
Employees
Officers
The intrinsic value of one AKYA stock under the Base Case scenario is 15.34 USD.
Compared to the current market price of 3.81 USD, Akoya Biosciences Inc is Undervalued by 75%.